Cardiac manifestations in a two‑generation family with Fabry disease (RCD code: III‑2B.2a)
Journal Title: Journal of Rare Cardiovascular Diseases - Year 2014, Vol 1, Issue 8
Abstract
Fabry disease (FD), which is also called angiokeratoma corporis difusum, ceramide trihexosidosis, and Anderson-Fabry disease, is an X-linked inborn error of metabolism of glycosphingolipid pathway. It is caused by the deficiency of the the lysosomal enzyme – hydrolasealpha-galactosidase A, which results in the accumulation and subsequent tissue deposition of globotriaosylceramide, the glycolipid substrate for alpha-galactosidase A. The incidence of the disease varies between 1:17,000 to 1:117,000 males in the Caucasian populations. The disease is less common among women, and if present the symptoms are milder. Enzyme replacement therapy of the agalsidase-A or agalsidase-ß offers a specific treatment for patients with FD. Since 2001 the ERT, using recombinant human alpha-galactosidase A, has become the most efficient and specific therapy, which address the underlying defect of FD. The guidelines on the ERT greatly vary among countries, the main reason being the high cost of this treatment. Pediatric patients firstly suffer from neurological involvement, manifesting as a persistent, neuropathic pain of the extremities, often misdiagnosed as a “growing pain”, as well as gastrointestinal disorders(diarrhea, nausea, vomiting). In the later stages other organs are becoming involved causing multi-organ failure renal insufficiency, cardiovascular impairment, cerebrovascular incidences, cutaneous changes (teleangiectasias, angiokeratomas and lymphoedema), malfunction of sensations organs (cornea verticillata, retinal vascular tortuosity) and other symptom like anhidrosis, sweating problems, heat collapse or depression. JRCD 2014; 1 (8): 27–31
Authors and Affiliations
Paweł Rubiś, Sylwia Wiśniowska-Śmiałek, Barbara Biernacka-Fijałkowska, Magdalena Kostkiewicz, Agata Leśniak-Sobelga, Piotr Podolec
Keywords
Related Articles
- EP ID EP245414
- DOI 10.20418/jrcd.vol1no8.155
- Views 126
- Downloads 0
Cardiac AL Amyloidosis (RCD code: III-3A.2a)
Primary systemic amyloidosis (AL amyloidosis) is the most common subtype of amyloidosis in developed countries. Amyloid fibrils deposition results from an abnormal secondary structure of immunoglobulin light chains produ...
The association between aortic stenosis and intestinal angiodysplasia – the Heyde’s Syndrome (RCD code: VIII-1)
Heyde’s syndrome is defined as a combination of gastrointestinal bleeding from a gastrointestinal angiodysplasia in patients with aortic stenosis. An acquired von Willebrand factor deficiency secondary to aortic stenosis...
62 year‐old woman with recurrent pleural and pericardial effusion (RCD code: III)
The spectrum of pericardial diseases consists of congenital defects, pericarditis (dry, effusive, effusive-constrictive, and constrictive), neoplasm, and cysts. The aetiological classification comprises: infectious peric...
Electrocardiographic abnormalities in patients with pulmonary sarcoidosis (RCD code: III)
Sarcoidosis is a systemic inflammatory disease characterized by the presence of noncaseating granulomas. Etiology of the disease remains unknown. From 3.7% to 54.9% patients with extra‑cardiac sarcoidosis have asymptomat...
3rd Symposium on Rare Cardiovascular Diseases – ESC Amsterdam 2013: Chairperson’s Perspective
The 3rd Satellite Symposiumon Rare Cardiovascular Diseases, which was organized by the Krakow Center for Rare Cardiovascular Diseases, was officially included in the Program of the 2013 ESC Congress and was held in the E...